Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 109 publications
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 15, 2026
Assessing Human Epidermal Growth Factor Receptor 2 in Urothelial Carcinoma: Insights From Clinical Practice Into Scoring Criteria, Histologic Subtypes, and Genomic Characteristics Across Disease Sites.
Journal: Archives of pathology & laboratory medicine
Published: April 21, 2026
Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma.
Journal: Science advances
Published: January 07, 2026
Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.
Journal: The Journal of urology
Published: October 27, 2025
Clinicopathologic and Prognostic Features of Sarcomatoid Urothelial Carcinoma: A Retrospective Study of 136 Patients With Emphasis on Early-Stage (pT1) Disease.
Journal: The American journal of surgical pathology
Published: September 15, 2025
Dynamics of Tumor-informed Circulating Tumor DNA and Association with Clinical Responses to Enfortumab and Pembrolizumab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Journal: European urology
Published: June 12, 2025
IK-175, an Oral Aryl Hydrocarbon Receptor Inhibitor, Alone and with Nivolumab in Patients with Advanced Solid Tumors and Urothelial Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 03, 2025
Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 18, 2025
Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.
Journal: Cancer research communications
Published: May 05, 2025
Neoadjuvant Chemotherapy for Upper Tract Urothelial Cancer.
Journal: European urology focus
Published: May 04, 2025
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 22, 2025
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 14, 2025
Last Updated: 09/26/2026